Therefore, the maintenance of Th2 responses by PPARγ seems to prevent the amplification of a more pathological Th17‐biased inflammation, suggesting PPARγ agonists could be used for targeting obesity‐related allergic diseases.5 The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.